MyFinsight
Home
Blog
About
Proceeds from the
issuance of convertible...
$29,100K
Proceeds from issuance of
common stock, net of...
$14,100K
Proceeds from exercise of
stock options
$806K
(-55.74%↓ Y/Y)
Net cash provided by
financing activities
$42,057K
(2209.56%↑ Y/Y)
Canceled cashflow
$1,987K
Net increase
(decrease) in cash and cash...
-$303,647K
(-10.09%↓ Y/Y)
Canceled cashflow
$42,057K
Proceeds from sales and
maturities of investments
$74,106K
(173.25%↑ Y/Y)
Acquired in-process
research and development
$30,000K
Stock-based compensation
expense
$8,619K
(-24.60%↓ Y/Y)
Accrued expenses
$7,938K
(54.17%↑ Y/Y)
Non-cash interest
expense on royalty...
$6,837K
Non-cash interest
expense on senior...
$2,054K
Prepaid expenses and
other assets
-$1,109K
(-38.28%↓ Y/Y)
Non-cash interest
expense on convertible...
$280K
Non-cash lease expense
$269K
(-39.69%↓ Y/Y)
Depreciation expense
$4K
(-88.57%↓ Y/Y)
Payments of debt issuance
costs for the senior...
$1,460K
Payments of other
offering costs for the atm...
$527K
Net cash used in
investing activities
-$287,704K
(-44.89%↓ Y/Y)
Net cash used in
operating activities
-$57,237K
(27.36%↑ Y/Y)
Canceled cashflow
$74,106K
Canceled cashflow
$57,110K
Effect of exchange rate
changes on cash and cash...
-$763K
(-164.93%↓ Y/Y)
Purchases of investments
$331,810K
(47.04%↑ Y/Y)
Net loss
-$111,456K
(-29.91%↓ Y/Y)
Payments of milestones
achieved pursuant to...
$30,000K
Accounts payable
-$1,334K
(85.51%↑ Y/Y)
Net amortization of
premiums and accretion of...
-$1,287K
(2.28%↑ Y/Y)
Operating lease
liabilities
-$270K
(39.46%↑ Y/Y)
Back
Back
Cash Flow
Zenas BioPharma, Inc. (ZBIO)
Zenas BioPharma, Inc. (ZBIO)
source: myfinsight.com